<DOC>
	<DOCNO>NCT00004052</DOCNO>
	<brief_summary>RATIONALE : Vaccines may make body build immune response kill cancer cell . PURPOSE : Phase II trial study effectiveness vaccine therapy treat patient chronic myelogenous leukemia .</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients With Chronic Myelogenous Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety immunogenicity multivalent tumor-specific breakpoint peptide vaccine patient chronic myelogenous leukemia . - Determine antileukemic effect vaccination peptide patient . OUTLINE : Patients receive bcr/abl breakpoint peptide vaccine QS21 adjuvant subcutaneously rotate site every 1-3 week ( day 0 , 7 , 21 , 35 , 56 ) 8 week . Treatment continue absence disease progression unacceptable toxicity . Patients demonstrate response week 10 may receive 3 additional monthly vaccination initiate within 8 week fifth dose . Patients demonstrate response vaccination 8 may receive 3 additional vaccination administer two-month interval . Patients follow 2 week . PROJECTED ACCRUAL : A total 24 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove chronic myelogenous leukemia Must ( 9 ; 22 ) translocation bcr/abl transcript , b3a2 breakpoint No accelerate blastic phase Must hematologic remission peripheral WBC le 20,000/mm^3 PATIENT CHARACTERISTICS : Age : Over 16 Performance status : Karnofsky 70100 % Life expectancy : Not specify Hematopoietic : See Disease Characteristics Absolute granulocyte count great 1,200/mm^3 Platelet count great 70,000/mm^3 Hemoglobin great 9.0 g/dL No active bleeding Hepatic : Bilirubin le 2.0 mg/dL Lactate dehydrogenase less 2 time normal Renal : Creatinine le 2.0 mg/dL Cardiovascular : No New York Heart Association class III IV heart disease Other : No uncontrolled active infection require antibiotic No serious illness No immunodeficiency prior bone marrow transplantation Not pregnant nursing PRIOR CONCURRENT THERAPY : Biologic therapy : At least 6 month since prior allogeneic autologous bone marrow transplantation Prior vaccination pentavalent peptide less study dose level allow At least 4 week since prior immunotherapy interferon , donor lymphocyte infusion , pentavalent vaccine Concurrent interferon allow Chemotherapy : At least 2 week since prior lowdose subcutaneous cytarabine At least 4 week since prior chemotherapy hydroxyurea No concurrent chemotherapy except hydroxyurea Endocrine therapy : No concurrent corticosteroid Radiotherapy : At least 4 week since prior radiotherapy No concurrent radiotherapy Surgery : No concurrent surgery Other : Concurrent imatinib mesylate allow No concurrent systemic therapy</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
</DOC>